Onderneming Aptose Biosciences Nasdaq
Aandelen
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
William Rice
CEO | Chief Executive Officer | 65 | 28-10-13 |
C. Payne
DFI | Director of Finance/CFO | 61 | 27-06-22 |
Chief Tech/Sci/R&D Officer | - | 01-11-19 | |
Rafael Bejar
CTO | Chief Tech/Sci/R&D Officer | 53 | 01-01-20 |
Investor Relations Contact | - | - | |
Marc Wiles
LAW | General Counsel | - | - |
Brooks Ensign
AUD | Comptroller/Controller/Auditor | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Denis Burger
BRD | Director/Board Member | 80 | 19-09-07 |
Bernd Seizinger
BRD | Director/Board Member | 67 | 13-09-22 |
Mark Vincent
BRD | Director/Board Member | 71 | 19-09-07 |
Director/Board Member | 74 | 15-12-14 | |
William Rice
CEO | Chief Executive Officer | 65 | 28-10-13 |
Warren Whitehead
BRD | Director/Board Member | 71 | 07-04-11 |
Carol Ashe
BRD | Director/Board Member | 66 | 15-08-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 16 309 393 | 13 210 854 ( 81,00 %) | 0 | 81,00 % |
Bedrijfsgegevens
Aptose Biosciences, Inc.
251 Consumers Road Suite 1105
M2J 4R3, Toronto
+647 479 9828
http://www.aptose.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-0,09% | 42,12 mld. | |
+49,62% | 42,05 mld. | |
-4,96% | 29,18 mld. | |
+11,18% | 26,02 mld. | |
-21,95% | 18,9 mld. | |
+8,61% | 13,21 mld. | |
+24,73% | 12,17 mld. | |
+28,31% | 12,16 mld. | |
-6,26% | 11,42 mld. |